Intraocular Pressure-Lowering Effects of Latanoprost and Brimonidine Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension: A Randomized Observer-Masked Multicenter Study

Abstract

Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment. However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure. Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects.

Adverse periocular reactions to five types of prostaglandin analogs

“…The method of comparing pictures of the left eye with those of the right eye (0-6.0%) provided results that were closer to the results obtained by slit lamp judgment. The frequency of changes in eyelashes by picture judgment was 0-53.8% 6-10,12,13 and 0-25.6% by slit lamp judgment, 4,5,11,15 indicating that the frequency was greater by picture judgment. The method of comparing pictures of the left eye with those of the right eye (8.0-54.0%) in this study was closer to the picture judgments of previous studies.…”

“…The appearance frequencies of eyelid pigmentation with the use of PG analogs are reported to be 0, 2 0.8, 3 In these previous studies, [2][3][4][5][6][7][8][9][10][11][12][13][14][15] there were variations in the frequency of the administration period, method used for judging adverse reactions (by slit lamp or images), and race. Owing to differences in the administration period, the appearance frequency of eyelid pigmentation was 1.5-2.9% 4 in patients with o3 months of medication use and 0-25.9% 2,3,[5][6][7][8]15 in patients with 43 months of medication use.…”

“…Owing to differences in the administration period, the appearance frequency of eyelid pigmentation was 1.5-2.9% 4 in patients with o3 months of medication use and 0-25.9% 2,3,[5][6][7][8]15 in patients with 43 months of medication use. The appearance frequency of changes in eyelashes was 0-33.8% 4,10,12,15 in patients with o3 months of use and 0.7-77% [5][6][7][8][9][10][11]13,14 in patients with 43 months of use. In this study, the administration period was 43 months for all five types of PG analogs, and the appearance frequency ranged from 0 to 6.0% for eyelid pigmentation and 8.0 to 54.0% for eyelash changes.…”

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] Of these, changes in eyelashes, eyelid pigmentation, iris pigmentation, hypertrichosis around the eye, appearance of iritis, and deepening of the upper eyelid sulcus are thought to be characteristic adverse reactions to PG analogs. The frequency of eyelid pigmentation was reported to be between 0 and 25.9%, [2][3][4][5][6][7][8][9] and eyelash bristles are reported to occur in 0-77.0% of patients [4][5][6][7][8][9][10][11][12][13][14][15] with PG analog use. However, no study has compared the frequency of occurrence of eyelid pigmentation and eyelash bristles with the use of five types of PG analogs.…”

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

“…64,67,68 The primary endpoint in most trials is the mean reduction in IOP from baseline. Because of the large number of clinical studies of variable scientific quality evaluating latanoprost 0.005%, bimatoprost 0.3% and travoprost 0.004% as mono-, concomitant or combination therapy for OH and OAG, 63,64,[68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83] selected randomized control trials and meta-analyses will be discussed in this review. Meta-analyses may be preferable in evaluating drug effectiveness.…”